000304502 001__ 304502
000304502 005__ 20250914022659.0
000304502 0247_ $$2pmid$$apmid:40931870
000304502 0247_ $$2ISSN$$a0390-6078
000304502 0247_ $$2ISSN$$a1592-8721
000304502 0247_ $$2doi$$aDOI:10.3324/haematol.2025.287697 
000304502 0247_ $$2doi$$aDOI:10.3324/haematol.2025.287697
000304502 0247_ $$2altmetric$$aaltmetric:181352533
000304502 037__ $$aDKFZ-2025-01891
000304502 041__ $$aEnglish
000304502 082__ $$a610
000304502 1001_ $$aFischer, Claudia$$b0
000304502 245__ $$aIGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
000304502 260__ $$aPavia$$bFerrata Storti Foundation$$c2025
000304502 3367_ $$2DRIVER$$aarticle
000304502 3367_ $$2DataCite$$aOutput Types/Journal article
000304502 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757593897_7394
000304502 3367_ $$2BibTeX$$aARTICLE
000304502 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304502 3367_ $$00$$2EndNote$$aJournal Article
000304502 500__ $$aepub
000304502 520__ $$aWe previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors. R110-bsAb spared polyclonal human B cells (as opposed to CD19-targeting Blinatumomab) as well as CD34+ human stem cells. Yet, R110- bsAb induced lower T cell activation than Blinatumomab with primary CLL cells likely due to lower expression of target antigen. In vivo, R110-bsAb specifically killed IGLV3-21R110-expressing cell lines and CLL cells while sparing peripheral blood mononuclear cells. These findings highlight bispecific antibodies as a potential off-the-shelf immunotherapy for high-risk CLL patients, offering selective targeting while preserving healthy B cells.
000304502 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304502 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000304502 7001_ $$aChen, Shih-Shih$$b1
000304502 7001_ $$aNimmerfroh, Johanna$$b2
000304502 7001_ $$aEugster, Anne$$b3
000304502 7001_ $$aStücheli, Simon$$b4
000304502 7001_ $$aSchultheiß, Christoph$$b5
000304502 7001_ $$aWidmer, Corinne$$b6
000304502 7001_ $$aHeim, Dominik$$b7
000304502 7001_ $$aKasenda, Benjamin$$b8
000304502 7001_ $$aPassweg, Jakob$$b9
000304502 7001_ $$0P:(DE-HGF)0$$aKobold, Sebastian$$b10
000304502 7001_ $$aEgli, Lukas$$b11
000304502 7001_ $$aCoianiz, Nicolò$$b12
000304502 7001_ $$aChijioke, Obinna$$b13
000304502 7001_ $$aChiorazzi, Nicholas$$b14
000304502 7001_ $$aFollo, Marie$$b15
000304502 7001_ $$aLäubli, Heinz$$b16
000304502 7001_ $$aPeipp, Matthias$$b17
000304502 7001_ $$aBinder, Mascha$$b18
000304502 773__ $$0PERI:(DE-600)2805244-4$$aDOI:10.3324/haematol.2025.287697$$pnn$$tHaematologica$$vnn$$x0390-6078$$y2025
000304502 909CO $$ooai:inrepo02.dkfz.de:304502$$pVDB
000304502 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000304502 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304502 9141_ $$y2025
000304502 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-05T07:07:08Z
000304502 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-05T07:07:08Z
000304502 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2023-06-05T07:07:08Z
000304502 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-20
000304502 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-20
000304502 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000304502 980__ $$ajournal
000304502 980__ $$aVDB
000304502 980__ $$aI:(DE-He78)MU01-20160331
000304502 980__ $$aUNRESTRICTED